<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200922048802N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-22</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Determination of the effect of licorice on Sex hormone, insulin and fasting blood sugar, blood lipids, depression, sleep quality and appetite in participants with polycystic ovary syndrome (PCOS) and overweight / obesity.</public_title>
      <acronym></acronym>
      <scientific_title>Determination of the effect of licorice extract on testosterone and Sex hormone binding globulin (SHBG), LH, FSH, Insulin, FBS, LDL, HDL, TG, Cholesterol, sleep quality, depression, and appetite in participants with polycystic ovary syndrome (PCOS) and overweight / obesity.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51912</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization: Simple Random unit: Individual Tool: Randomized Tables A balanced block method is used to allocate concealment so that the number of samples assigned to each of the groups is equal, Blinding description: Supplements of licorice and placebo in the same capsules in terms of size, color and shape Encodes A and B on supplements and placebo.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Polycystic ovarian syndrome. Condition 2: Overweight and obesity.</hc_freetext>
      <i_freetext>Intervention 1: People in this group will recieve three 500 mg capsules of licorice daily for 8 weeks. Intervention 2: Control group: People in this group will recieve three 500 mg capsules of placebo daily for 8 weeks.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hadis Hooshmandi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of health, Shahid Sadoughi university of medical sciences, Shohadaye Gomnam Blvd., Alam Sq,</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915173160</zip>
        <telephone>+98 35 3820 9100</telephone>
        <email>hadis.july.1994@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Azadeh Nadjarzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of health, Shahid Sadoughi university of medical sciences, Shohadaye Gomnam Blvd., Alam Sq,</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8915173160</zip>
        <telephone>+98 35 3820 9100</telephone>
        <email>azadehnajarzadeh@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age between 18 to 45
BMI 25-35 kg/m2
Polycystic ovary syndrome based on Rotterdam criteria</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Blood pressure equal or than 90/140 mmHg
Cardiovascular diseases with regular drug use, liver, kidney and thyroid disorders, diabetes
Taking multi vitamin-mineral supplements
Smoking
Antioxidant and herbal treatments during the last 3 months
Pregnancy and lactation
Consumption of licorice more than 300 grams per week
Hyper androgenism includes hereditary adrenal hyperplasia, Cushing's syndrome, hyperprolactinemia, and hypothyroidism or androgen-secreting tumors
History of allergy to licorice or any of its components</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
      <hc_code>E66</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
      <hc_keyword>Overweight and obesity</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>People in this group will recieve three 500 mg capsules of licorice daily for 8 weeks.</i_keyword>
      <i_keyword>Control group: People in this group will recieve three 500 mg capsules of placebo daily for 8 weeks.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Serum testosterone level. Timepoint: at the beginning and end of  8-weeks intervention period. Method of measurement: ELISA Kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Serum SHBG level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.</sec_outcome>
      <sec_outcome>Serum FSH level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.</sec_outcome>
      <sec_outcome>Serum LH level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.</sec_outcome>
      <sec_outcome>Serum insulin level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: ELISA Kit.</sec_outcome>
      <sec_outcome>Serum FBS level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.</sec_outcome>
      <sec_outcome>Serum LDL level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.</sec_outcome>
      <sec_outcome>Serum HDL level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.</sec_outcome>
      <sec_outcome>Serum TG level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.</sec_outcome>
      <sec_outcome>Serum Cholesterol level. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Biochemical analysis.</sec_outcome>
      <sec_outcome>BDI questionnaire. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Likert scale.</sec_outcome>
      <sec_outcome>Pittsburgh Sleep Quality Index (PSQI). Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Likert scale.</sec_outcome>
      <sec_outcome>The Council on Nutrition Appetite Questionnaire (CNAQ). Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Likert scale.</sec_outcome>
      <sec_outcome>Body composition. Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Body analyzer.</sec_outcome>
      <sec_outcome>Anthropometric measurements (height, weight, BMI, waist circumference, hip circumference, abdominal / hip ratio). Timepoint: at the beginning and end of 8-weeks intervention period. Method of measurement: Body analyzer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-02-18</approval_date>
        <contact_name>Ethics committee of Shahid Sadoughi University of Medical Sciences Yazd</contact_name>
        <contact_address>School of health, Sadoughi University of Medical Sciences, Shohadaye Gomnam Blvd., Alem Sq. Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
